New Horizons in Ovarian Cancer: Expert Insights into the Role of Genetic Biomarkers in Precision Therapy
Attendees of these regional meetings will gain an appreciation of the genes involved in the DNA damage response pathways and their role in tumorigenesis, the latest guidelines on genetic testing/counseling for mutations in this pathway, and the clinical implications of testing results (such as the use of PARP inhibitor for treatment). There will also be extensive discussion about the evolving role of the OB/GYN practitioner in genetic testing/counseling and management of ovarian cancer survivors on PARP inhibitor therapy.
Presented by Creative Educational Concepts, Inc.
Supported through an independent educational grant from AstraZeneca and Merk.
This activity is targeted to gynecologists, obstetricians, and other related healthcare professionals attending the 2021 American College of Obstetricians and Gynecologists (ACOG) Clinical District Meetings.
- Review the DNA damage response (DDR) pathway and its role in tumorigenesis of ovarian cancers and outline the various mutations that cause defects in this pathway.
- Review the latest clinical recommendations on genetic testing and counseling in ovarian cancer and discuss the therapeutic implications of identifying mutations in the DDR, as well as other relevant markers of genomic instability (e.g., HRD).
- Discuss current and emerging clinical data regarding the safety and efficacy of PARP inhibitors in ovarian cancer patients.
- Assess the evolving role of OB/GYN practitioners for genetic testing/counseling in patients who are at risk for or have deficiencies in the HRR pathway and discuss multidisciplinary strategies to ensure the appropriate management of patients on PARP inhibitors.
5 min Welcome and Introductions/Pre-test
15 min The DNA Damage Response Pathway: BRCA and Beyond
15 min PARP Inhibitors in Ovarian Cancer Treatment: A Possible Achilles Heel?
20 min Improving Patient Outcomes in Ovarian Cancer: Practical Strategies for the OB/GYN Practice
5 min Conversations with the Experts/Audience Q&A/Post-test
Ursula A. Matulonis, MD
Medical Director and Program Leader, Medical Gynecologic Oncology Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Dr. Matulonis is Medical Director and Disease Center Leader of the Medical Gynecologic Oncology Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts. She also is the interim director of the Susan F. Smith Center for Women’s Cancers at Dana-Farber. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in the genetic changes in ovarian cancer and how that can lead to rationale drug development and selection.
Dr. Matulonis is Principal Investigator (PI) of several therapeutic clinical trials and translational studies for ovarian cancer. She is the overall PI on a Program Project Development Grant funded by the Ovarian Cancer Research Foundation entitled “Rational Combinations of Novel Biologic Agents for Ovarian Cancer Therapy.” She is the PI on the project “Genetic Similarities between Serous Ovarian Cancer and Triple-Negative Breast Cancer” funded by the Breast Cancer Research Foundation. Dr. Matulonis serves on the National Comprehensive Cancer Network Recommendation and Guideline committee for ovarian cancer, the Massachusetts ovarian cancer Task Force, the Gynecologic Oncology Group ovarian committee, the National Cancer Institute Ovarian Cancer Task Force, the Scientific Advisory Board of the Ovarian Cancer Research Foundation, the Scientific Board of the Clearity Foundation, and is Medical Director and a board member for the non-profit organization Ovations for the Cure. She is a recipient of the Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler “Extra Mile” Award, the Leonard P. Zakim Patient Advocacy Award, and the Susan M. Love Award from Fenway Health.
After receiving her medical degree from Albany Medical College in Albany, New York, she completed an internship and residency at the University of Pittsburgh in Pittsburgh, Pennsylvania, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ursula Matulonis, MD–has disclosed he is a consultant for AstraZeneca, Merck, NextCure, and Novartis. He receives financial or material support from DSMB and Symphogen.
Angeles Alvarez Secord, MD– Disclosures to come.
Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron and Seagen. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers bureau for ONC Live and Curio Science.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live, virtual educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Upon completion of a CE request form, statements of credit for physicians will be issued.
This is an independent CME Satellite Event and is not part of the official ACOG District XII 2021 Annual District Meeting.
This webinar will be presented by CEC Oncology and is supported through independent educational grants from AstraZeneca and Merck.
There is no fee to participate; registration required.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation